Objectives The main aims of this systematic review were to identify all relevant literature on
clinical efficacy for biological medications in patients with psoriasis and to conduct an up-to …

What is known and Objective Psoriasis is a chronic skin disease for which there is an
increasing range of treatment options. Biological agents (ustekinumab, adalimumab …

Objectives: As no direct comparisons have been made between infliximab and ustekinumab,
the present study's aim was to estimate these drugs' relative efficacy in the treatment of …

Background Multiple biological therapies are approved for the treatment of moderate‐to‐
severe psoriasis. Objectives To assess the short‐term efficacy of biological treatments for …

Background Ustekinumab, a novel monoclonal antibody for the treatment of moderate to
severe plaque‐type psoriasis, has recently received regulatory approval in Europe, bringing …

The aim of the present meta‑analysis was to systematically assess the efficacy of the various
treatments available for moderate to severe psoriasis. PubMed and Embase databases …

Health care managers and hospital pharmacists are increasingly compelling prescribers to
use medication substitutes. This policy becomes particularly evident when the agents are …

Background: A comprehensive assessment of the risk-benefit profile of biologic agents in
psoriasis is lacking. We conducted a network meta-analysis of randomized trials on biologic …

Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic
manifestations. Safe and effective long-term treatments are needed. Biologic treatments that …

Background The rapid expansion of psoriasis biologics has led to an urgent need to
understand their relative efficacy and tolerability to inform treatment decisions better and …